Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough

Though this study met its primary endpoint and oral selexipag was approved as a treatment for inoperable CTEPH patients in Japan, the overall results and scope of this study do not justify a valid position for selexipag in the treatment armamentarium.https://bit.ly/3INAYgO